ライフサイエンスコーパス: keratoacanthoma

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ffect is not associated with regression of a keratoacanthoma.

2 associated with squamous cell carcinomas and keratoacanthomas.

3 ell carcinoma (65 [19%] of 337 patients) and keratoacanthomas (34 [10%]), rash (30 [9%]), and abnorma

4 benign and malignant human tumors, including keratoacanthoma and squamous cell carcinoma.

5 in high-fat-fed mice decreased the number of keratoacanthomas and squamous cell carcinomas per mouse

6 ession of EJras was detectable in all of the keratoacanthomas and squamous cell carcinomas.

7 ene in both the initiation and regression of keratoacanthoma, and in the development of squamous cell

8 cerous epidermis away from tumors, by 68% in keratoacanthomas, and by 224% in squamous cell carcinoma

9 idermal tumors such as verrucous papillomas, keratoacanthomas, and squamous cell carcinomas (SCC).

10 eaction, hair changes, verrucous papillomas, keratoacanthomas, and squamous cell carcinomas.

11 Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated

12 Benign skin keratoacanthomas arose and often regressed in treated tr

13 cutaneous squamous cell carcinomas (cSCC) or keratoacanthomas as a side effect in 18% to 30% of patie

14 e F1 transgenic progenies developed multiple keratoacanthomas at about 3 days after birth.

15 ficient mice are predisposed to formation of keratoacanthomas, cutaneous tumors thought to originate

16 describe an original mouse model of invasive keratoacanthoma driven by skin-specific expression of th

17 inically, we found that human differentiated keratoacanthomas expressed low levels of uPAR and high l

18 unding induces benign tumors (papillomas and keratoacanthomas) in InvEE mice.

19 xpression is reduced in both mouse and human keratoacanthomas, indicating tumor-suppressive propertie

20 Keratoacanthoma (KA) is a variant of cutaneous squamous

21 nd invasive squamous-cell carcinomas (SCCs), keratoacanthoma (KA), and normal skin samples from both

22 ntaneously self-regressing tumour, cutaneous keratoacanthoma (KAs), to identify physiological mechani

23 mas with BRAF V600E mutations but may induce keratoacanthomas (KAs) and cutaneous squamous cell carci

24 re have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizum

25 possibly accounting for up to 60% of cSCC or keratoacanthoma lesions with RAS mutations, but other co

26 Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combin

27 ib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensiti

28 which clinically and histologically resemble keratoacanthomas or well-differentiated squamous cell ca

29 Grade 3 toxicities included keratoacanthomas, rash, fatigue, and arthralgia.

30 usly regressed in about 2 months, similar to keratoacanthoma regression in humans.

31 nt in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with v

32 situ and adult mice developed papillomas and keratoacanthomas, the latter having a high frequency of

33 uamous cell carcinomas (well-differentiated, keratoacanthoma type) at uninvolved sites including the

34 eous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients.

35 a relatively poor prognosis; in contrast, a keratoacanthoma, which eventually regresses, does not me

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。